Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies

Figure 1

Annualized bleeding rate for all bleeds by dosing group. Q1 = quartile 1; Q3 = quartile 3.